Description
Consider this assay for targeted analysis of cardiovascular disease markers. The Human Cardiovascular Disease Panel 6-Plex Discovery Assay® Array measures six biomarkers simultaneously related to cardiovascular inflammation and coagulation: ADAMTS13, SAA, sP-Selectin, sICAM-1, sVCAM-1 and D-Dimer.
Indications:
Use this test to identify relevant therapy targets, determine disease mechanisms, and diagnose or monitor the following conditions associated with vascular health, coagulation, and inflammation:
- Thrombotic Disorders: Assess conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and disseminated intravascular coagulation (DIC), where D-Dimer and ADAMTS13 levels can indicate abnormal clot formation and breakdown.
- Cardiovascular Diseases: Monitor cardiovascular conditions such as atherosclerosis, myocardial infarction, and stroke, where biomarkers like sICAM-1, sVCAM-1, and sP-Selectin indicate endothelial dysfunction and inflammation.
- Inflammatory Diseases: Evaluate chronic inflammatory conditions such as rheumatoid arthritis, inflammatory bowel disease (IBD), and systemic lupus erythematosus (SLE), where Serum Amyloid A (SAA) and soluble adhesion molecules (sICAM-1, sVCAM-1) can reflect the systemic inflammatory state.
- Sepsis and Critical Illness: Diagnose and monitor sepsis and related critical illnesses, where elevated levels of D-Dimer, SAA, and soluble adhesion molecules (sICAM-1, sVCAM-1, sP-Selectin) can indicate systemic inflammation, endothelial activation, and coagulopathy.
- Chronic Kidney Disease (CKD): Assess endothelial dysfunction and inflammation in CKD, where elevated levels of sICAM-1, sVCAM-1, and SAA are indicative of chronic inflammatory processes and vascular complications.
Consider using the Long COVID Vascular Health 18-Plex Panel for the most comprehensive vascular health profile available.
A number of biomarkers detected in the SAA/Cardiovascular Disease 6-Plex Panel are specifically associated with coagulation, which make serum an unacceptable sample type for this assay. The SAA/Cardiovascular Disease 6-Plex Panel is recommended for plasma only, EDTA preferred.
Key Features:
- Focused Biomarker Coverage: Provides a focused analysis of two key biomarkers, ensuring a thorough diagnostic approach.
- CLIA Certified for Clinical Use: As a CLIA certified laboratory, we provide a panel that meets the highest standards of accuracy and reliability for clinical diagnostics.
- Versatility: Use this panel to investigate acute phase inflammatory detection, chronic inflammatory diseases.
- Sample flexibility: Are available for PLASMA-EDTA and CSF (SAA only) samples.
- Affordable Assay Services: We offer some of the most affordable assay services available, making advanced diagnostics accessible for clinical applications.
- Swift and Reliable Turnaround Time: We pride ourselves on a rapid turnaround time, with results typically delivered within 5 business days of receiving your specimen and payment.
Discover the power of precision with our SAA/Cardiovascular Disease 6-Plex Panel, expertly designed for the Luminex® 200™ platform. This cutting-edge technology enables the simultaneous detection of multiple biomarkers from a minimal single sample, delivering comprehensive insights with unmatched efficiency.
Certified Excellence in Diagnostic Testing
Eve Technologies is certified by the Centers for Medicare & Medicaid Services (CMS) as a High Complexity International Laboratory under the Clinical Laboratory Improvement Amendments (CLIA), specializing in Diagnostic Immunology with a subspecialty in General Immunology (CLIA# 99D2283230). Additionally, we hold a clinical and public health laboratory license with the California Department of Public Health (COS-90013367). Our certification underscores our commitment to rigorous standards.
Clinicians: Please check with your State Agency to determine if additional licensure or registration requirements may apply.
Regulated tests: Ensuring Quality and Accuracy
The LDT (Lab Developed Test) designation highlights that our tests are regulated by the Centers for Medicare & Medicaid Services (CMS) under CLIA, ensuring they meet stringent quality and accuracy standards. Unlike commercially distributed tests, which undergo FDA approval, our LDTs are developed and validated within our laboratory to provide specialized and reliable diagnostic insights tailored to your needs. This distinction underscores our commitment to maintaining the highest standards in testing and personalized care.
! The interpretation of these test results should be correlated with clinical findings and other diagnostic tests. Biomarker levels can vary due to many biological, physiological, and diurnal factors; their clinical significance must be assessed by a qualified healthcare professional. This information is not intended to be used as the sole basis for diagnosis or treatment decisions. ​